EXPERIENCE WITH THE HIV PROTEASE INHIBITOR FOSAMPRENAVIR IN RUSSIAN PRACTICE

Objective. To evaluate the efficiency and hepatotoxicity of antiretroviral therapy (ARVT) regimens containing fosamprenavir and ritonavir (FPV/r) in a dose of 1400/100 mg once daily for 48 weeks. Subjects and methods. The data of 87 HIV-infected patients were analyzed. The proportion of patients with undetectable viral load, the levels of CD4 lymphocytes at 12, 24, 36, and 48 weeks, those of liver enzymes and aspartate aminotransferase to platelet ratio index (APRI) were estimated. Results. A viral load reduction was achieved in the vast majority (95.4%) of the patients at 48 weeks of therapy. The median increase in CD4 lymphocytes was 156 [43-257] cells/pl at that moment. No significant rise was found in the level of liver enzymes; there was even some reduction in the levels of ASAT and total and conjugated bilirubin. ARVT was not discontinued because of grade 3-4 hepatotoxicity. The parameters of the blood lipid spectrum were stable. In the average, there was no increase in APRI > 1.5, which indirectly confirms that FPV has no significant effect on the development of hepatic fibrosis. Conclusion. Once-daily FPV/r in the ARVT regimens showed high immunological and virological efficiencies, no negative impact on the liver, as well as good tolerability in co-infected patients.

HIV infection, antiretroviral therapy, protease inhibitors, fosamprenavir